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Summary Of 311 colorectal cancers diagnosed in 1984-86 in the county of Ostergotland, Sweden, 179 were
included in a case-control study, and, of these, 70 were investigated using immunohistochemical staining for
p53 gene mutations. Alcohol use as well as medication with hydralazine-containing antihypertensive drugs, but
not heredity were associated with p53 staining. The study is offered to illustrate the possible value of
investigating molecularly defined tumour subtypes in relation to specific risk factors.
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Colorectal cancer has been the subject of many epidemiolo-
gical and experimental studies mainly focusing on its relation
to dietary factors, although several have also addressed the
subject of occupational exposures (Potter et al., 1993).
Colorectal cancer has turned out to be an excellent system
for studying mutations and target genes in the development
and progression of human cancer (Fearon and Vogelstein,
1990). The tumour-suppressor gene p53 is frequently mutated
and inactivated in colorectal cancers as in about half of all
types of cancer (Greenblatt et al., 1994). Neoplastic cells
carrying missense mutations in exons 5 -8 ofthe p53 gene are
easily detected with an immunohistochemical technique
(immunostaining) because most of these mutations are
associated with a dramatically increased half-life of the p53
protein (Rodrigues et al., 1990; Levine et al., 1991). In
contrast, the p53 protein level is low in normal cells and
essentially undetectable by immunohistochemical techniques.
In this pilot study, we have combined molecular genetic
data with epidemiological to investigate specific risk factors
and their possible mechanisms of action in colorectal cancer,
as previously proposed (Axelson and Soderkvist, 1991).
Materials and methods
The data in this study are derived from two different studies,
each considering colorectal cancer in the county of Ostergot-
land, Sweden. The first of these is a case-control study
(Arbman et al., 1993) of 200 patients treated for
adenocarcinoma of the colon or rectum at the surgical
departments in the county between 1984 and 1986. Originally
311 patients fulfilled the criteria, and of these, 200 received a
questionnaire at the time of treatment. The patients who did
not receive a questionnaire were either too sick or refused to
participate. The controls included both 600 randomly drawn
population controls and 400 hospital controls, with hernias
and anal disorders. All cases and controls were below 75
years of age. A questionnaire interview of all subjects covered
occupational history, food and drinking habits and medical
history.
Out of the 200 cases, 400 hospital controls and 600
population controls originally enrolled in the study, 22 cases,
24 hospital controls (nine with anal diseases and 15 with
hernias) and 131 population controls did not return the
questionnaire despite two mailed reminders. One patient, five
hospital controls and 39 population controls were excluded
for reasons such as living abroad or living in prisons or
institutions for long periods of time. The two control groups
were compared and found to be very similar with regard to
the various exposures and were therefore merged.
The second study examined the prognostic significance of
p53 expression in colorectal cancers (Sun et al., 1992). This
study involved 293 cases of colorectal adenocarcinoma
diagnosed in the department of Pathology, University
Hospital of Linkoping between 1972 and 1986 and aged
33-93 years. The immunohistochemical staining method
used is described elsewhere (Sun et al., 1992). Nuclear p53
positivity was defined as staining of the nucleus, irrespective
of the percentage of positive cells.
Seventy cases, 29 with staining and 41 without staining
(five cases with only cytoplasmic staining were excluded),
were present in both studies and were compared with the
controls, following a study design described elsewhere
(Axelson and S6derkvist, 1991; Axelson, 1994). The
exposures considered here have all been associated with a
colorectal cancer risk in other studies.
Odds ratios (OR), adjusted for age and sex, along with
95% confidence intervals (CI95) were calculated by logistic
regression. Since sedentary work has been associated with
increased risk for colorectal cancer, a variable for physical
activity was included as described by Vena et al. (1985).
Results
Among the 70 cases with colorectal cancer, 29 (42%) revealed
p53-positive staining with similar sex distribution for p53-
positive and p53-negative tumours. The mean age was 64
years for both p53-positive cases and p53-negative cases
versus 58 years for controls, differences adjusted for in the
analysis. Thirty-eight (54%) of the cases had colon cancer
and 32 (46%) had rectal cancer. Among the p53-negative
cases 24 (58%) had colon cancer. With regard to p53
positivity, 14 (48%) of the 29 had colon cancer.
In contrast to some other studies (Potter et al., 1993), no
overall risk from alcohol consumption can be seen in this
study, but when p53 status was considered, an increased risk
for p53-positive tumours and alcohol intake was indicated
(OR =3.4, C195 1.1 - 10), but not for p53-negative cases,
(OR=0.61 C195 0.3-1.2) (Table I). Medication with
antihypertensive drugs containing hydralazine was strongly
associated with p53-positive tumours (OR= 15, C195 2.5-
91), although in small numbers.
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Table I Case-control evaluations for some determinants regarding 29 cases with expressed, i.e. inactivated, p53 gene (p53 positive), 41 cases
without expression of the p53 gene (p53 negative) and 801 controls. The cases and controls were stratified on age (<51 years, 51-65 years and
>65 years) and sex. Number of exposed cases and controls shown in table
ORa (95% CI) for p53 positive OR' (95% CI) for p53-positive OR' (95% CI) for p53-nega-
and p53 negative vs controls vs controls; tive
Determinants Exp. cases/exp. controls Exp. cases/exp. controls vs controls;
Exp. cases/exp. controls
Alcohol 1.1 (0.6-1.9) 3.4 (1.1-10) 0.61 (0.3-1.2)
41/478 22/478 19/478
Antihypertensive drugs 6.0 (1.0-35) 15 (2.5-91) 0
with hydralazine 2/4 2/4 0/4
Iron supplementation 4.9 (1.1-21) 0 8.7 (2.0-38)
3/8 0/8 3/8
Years of sedentary work
0
1 -20 44/477 20/477 24/477
>20 1.0 (0.5-2.1) 0.88 (0.3-2.5) 1.2 (0.5-3.0)
12/185 5/184 7/184
1.2 (0.6-2.2) 0.71 (0.2-2.1) 1.6 (0.7-3.5)
14/138 4/138 10/138
Close relatives with colorectal 3.1 (1.1-9.0) 0 5.7 (1.9-17)
cancer, ICD code: 153, 154 5/19 0/19 5/19
aLogistic odds ratio. bReference category. CI, confidence interval.
The overall risk for colorectal cancer and intake of drugs
for iron supplementation was elevated (OR=4.9, C195 1.1-
21) in this study and even more for p53-negative cases
(OR=8.7, C195 2.0-38). Sedentary work appeared with a
low risk for the p53-positive cases (OR=0.71, C195 0.2-2.1
for >20 years of sedentary work) (Table I). The earlier found
increased risk for sedentary work for more than 20 years
(Arbman et al., 1993), was carried by the p53-negative cases
(OR= 1.6, C195 0.7-3.5) in this study.
Cases reporting colorectal cancers among close relatives
(parent, sibling or children), and who might therefore be
members of a family with a hereditary form or colorectal
cancer (i.e. familial adenomatous polyposis or hereditary
non-polyposis colon carcinoma) were all p53 negative
(OR=5.7, C195 1.9- 17).
Discussion
The numbers are small in this study, but nevertheless, the
observed distribution of p53-positive and p53-negative cases
in relation to exposure might reflect different pathways in the
carcinogenic process. The frequency of p53-positive cases
(42%) is almost the same as in the prognostic study (39%)
(Sun et al., 1992), suggesting that p53 distribution per se is
not skewed among the cases despite limited numbers.
Another weakness of this study could be that positively
stained tumours are occasionally found that do not carry any
missense mutations. This suggests that there are also
alternative mechanisms for abnormal stabilisation of the
p53 protein, such as binding with cellular proteins or
increased gene expression (Greenblatt et al., 1994; Levine et
al., 1991). Furthermore, frame shift or chain-terminating
mutations in the coding sequences often result in an absent,
unstable or truncated protein, which is undetectable by
immunostaining. Therefore, immunoreactivity appears as an
approximate indicator of tumours for an altered p53 gene
function. More conclusive results can only be obtained after
sequencing of the gene and/or functional assays (Ishioka et
al., 1993).
Although no overall risk from alcohol appeared as was the
case in other studies (Potter et al., 1993), the separate analysis
revealed an increased risk for p53-stained tumours (Table I).
Medication with antihypertensive drugs containing hydrala-
zine showed an association with p53 positivity. Antihyper-
tensive medication has also appeared as a risk factor for
colon and rectal cancer in earlier case-control studies,
(Axelson et al., 1982; Kaufman et al., 1989). Hydralazine is
mutagenic and carcinogenic (Toth, 1978) and induces DNA
damage after enzymatic activation, possibly due to formation
of a hydralazyl radical (Yamamoto, 1991). Hydralazine may
therefore induce mutations in the p53 gene in colonic cells,
stimulating tumour growth or selectively promoting the
growth of p53-mutated colonic cells (and the same may be
true for alcohol).
Colon cancer has been associated with high iron stores in
the body (Stevens et al., 1988), which to some extent might
support the possibility of an increased risk from iron
supplementation as found in this study. There was no
inactivation of the p53 gene with regard to iron supplementa-
tion, so to the extent that our data reflect a true relationship,
there may instead be an activation of proto-oncogenes or
inactivation of other tumour-suppressor genes or some
epigenetic mechanism.
The decreased risk for the p53-positive cases in relation to
sedentary work is somewhat surprising, since sedentary work,
or low physical activity, is normally considered to be a risk
factor for colon cancer (Arbman et al., 1993; Fredrikson et
al., 1989; Vena et al., 1985; Potter et al., 1993). In the original
case-control study (Arbman et al., 1993), sedentary work
was associated with a decreased risk for rectal cancer whereas
an increased risk was seen for colon cancer.
Recently, the genes responsible for both familial
adenomatous polyposis and hereditary non-polyposis
colon carcinoma have been identified (Kinzler et al.,
1991; Groden et al., 1991; Altonen et al., 1993; Ionov et
al., 1993). Inactivation of these genes could be the critical
and rate-limiting steps in colorectal cancer cases with a
family history rather than inactivation of the p53 gene.
None of the five cases with relatives having colorectal
cancer were p53 positive in the present study but new
studies with larger numbers are required for a more
definite conclusion.
The p53 tumour-suppressor gene has been found
inactivated in many types of cancers, probably reflecting
an important role of this gene in tumorigenesis. Inactivation
of the p53-gene might be a late event in colorectal
carcinogenesis, suggesting that the observed risk factors forColwoct_l Cmm and Oem p53 gae
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p53 mutated cases represent exposures that are important
for promotion or progression rather than initiation of the
carcinogenic process. Recent studies also show a remarkably
specific interaction between certain environmental carcino-
gens and mutational patterns in the p53-gene (Greenblatt et
al., 1994).
So-called molecular epidemiology, as illustrated here, is
likely to become a powerful technique for studying critical
target genes and mutational patterns in different genes, such
as p53, in relation to certain exposures. Such studies may
reveal exposures associated with molecularly defined tumour
subtypes and also provide a better understanding of tumour
pathogenesis.
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